Once a floundering big pharma with looming patent cliffs and a pitiful pipeline, CEO Pascal Soriot has remade AstraZeneca (NYSE: AZN )
in a relatively short period of time. Patent cliffs are still likely
to compress revenue for the next year, but AstraZeneca now boasts an
appealing pipeline targeting a host of therapeutic classes, including an
immuno-oncology pipeline that holds up pretty well to comparisons with Bristol-Myers (NYSE: BMY ) , Merck (NYSE: MRK ) , and Roche (NASDAQOTH: RHHBY ) (Mr. Soriot's former employer).
Please continue here:
AstraZeneca PLC's Renovation Plan Fully Underway
No comments:
Post a Comment